Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 28;11(3):686.
doi: 10.3390/jcm11030686.

Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996-2015

Petra Anna Golovics  1   2 , Christine Verdon  1 , Panu Wetwittayakhlang  1   3 , Christopher Filliter  4 , Lorant Gonczi  5 , Gustavo Drügg Hahn  1   6 , Gary E Wild  1 , Waqqas Afif  1 , Alain Bitton  1 , Talat Bessissow  1 , Paul Brassard  4   7 , Peter L Lakatos  1   5
Affiliations

Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996-2015

Petra Anna Golovics et al. J Clin Med. .

Abstract

Background: Chronic inflammatory diseases are linked to an increased risk of atherothrombotic events, but the risk associated with inflammatory bowel disease (IBD) is controversial. We therefore examined the risk of and risk factors for myocardial infarction (MI) and stroke in IBD patients.

Methods: We used the public health administrative database from the Province of Quebec, Canada, to identify IBD patients newly diagnosed between 1996 and 2015. The incidence and prevalence of MI and stroke in IBD patients were compared to those for the Canadian population.

Results: A cohort of 35,985 IBD patients was identified. The prevalence but not incidence rates of MI were higher in IBD patients (prevalence: 3.98%; incidence: 0.234) compared to the Canadian rates (prevalence: 2.0%; incidence: 0.220), while the prevalence and incidence rates of stroke were not significantly higher in the IBD patients (prevalence: 2.98%; incidence: 0.122, vs. Canadian rates: prevalence: 2.60%; incidence: 0.297). We identified age, female gender, hyperlipidemia, diabetes, and hypertension (p < 0.001 for each) as significant risk factors associated with MI and stroke in IBD. Exposure to biologics was associated with a higher incidence of MI (IRR: 1.51; 95% CI: 0.82-2.76; p = 0.07) in the insured IBD population.

Conclusions: An increased prevalence but not incidence of MI and no increased risk of stroke were identified in this population-based IBD cohort.

Keywords: incidence; inflammatory bowel disease; myocardial infarction; prevalence; risk factor; stroke.

PubMed Disclaimer

Conflict of interest statement

P.A.G. has been a speaker for AbbVie, Takeda, Fresenius, and Ferring. C.V. has been a speaker for Janssen. P.W. has been a speaker and/or advisory board member for Takeda, Pfizer, Janssen, Ferring, A. Menerini, and MSD. T.B. has been a speaker or advisory board member for Takeda, Janssen, Abbvie, Merck, Pfizer, Pendopharm, Ferring, Shire, Sandoz, BMS, and Roche. W.A. has been a speaker for Janssen, Prometheus, Dynacare, Takeda, and AbbVie Theradiag. A.B. has been a member of Advisory Boards for Abbvie, Pfizer, Takeda, Janssen, and Merck, and speaker’s bureaus for Abbvie, Janssen, Takeda, and Pfizer. P.L.L. has been a speaker and/or advisory board member for AbbVie, Arena, Falk Pharma GmbH, Ferring, Genetech, Janssen, Kyowa Hakko Kirin Pharma, Mitsubishi Tanabe Pharma Corporation, MSD, Pfizer, Roche, Shire, Takeda, and Tillots, and has received unrestricted research grants from AbbVie, MSD, and Pfizer. C.F., L.G., G.D.H., G.E.W. and P.B. declare no conflicts of interest.

References

    1. Peters M.J.L., Symmons D.P.M., McCarey D., Dijkmans B.A.C., Nicola P., Kvien T.K., McInnes I.B., Haentzschel H., Gonzalez-Gay M.A., Provan S., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum Dis. 2010;69:325–331. doi: 10.1136/ard.2009.113696. - DOI - PubMed
    1. Lee J.L., Sinnathurai P., Buchbinder R., Hill C., Lassere M., March L. Biologics and cardiovascular events in inflammatory arthritis: A prospective national cohort study. Arthritis Res. Ther. 2018;20:171. doi: 10.1186/s13075-018-1669-x. - DOI - PMC - PubMed
    1. Yang Z.-S., Lin N.-N., Li L. The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: An Updated Meta-Analysis. Clin. Rev. Allergy Immunol. 2016;51:240–247. doi: 10.1007/s12016-016-8560-9. - DOI - PubMed
    1. Roubille C., Richer V., Starnino T., McCourt C., McFarlane A., Fleming P., Siu S., Kraft J., Lynde C., Pope J., et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis. Ann. Rheum. Dis. 2015;74:480–489. doi: 10.1136/annrheumdis-2014-206624. - DOI - PMC - PubMed
    1. Bernstein C.N., Blanchard J.F., Houston D., Wajda A. The incidence of venous thromboembolic disease among patients with IBD: A population-based study. Thromb Haemost. 2001;85:430–434. - PubMed

LinkOut - more resources